General Information of Drug Combination (ID: DCZXJZA)

Drug Combination Name
Leuprolide Goserelin
Indication
Disease Entry Status REF
Breast Cancer Phase 3 [1]
Component Drugs Leuprolide   DM5XPIJ Goserelin   DMAT8CG
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Leuprolide
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Approved [2]
Prostate cancer 2C82.0 Approved [3]
Endometriosis GA10 Investigative [2]
Leuprolide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leutinizing-hormone-releasing hormone (GNRH1) TT0ID4A GON1_HUMAN Activator [6]
------------------------------------------------------------------------------------
Leuprolide Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Thyroxine-binding globulin (SERPINA7) OTUYVTSU THBG_HUMAN Increases ADR [7]
Thyroid peroxidase (TPO) OTJJLL20 PERT_HUMAN Increases ADR [7]
Protein bric-a-brac 2 (bab2) OTNNK0KI BAB2_DROME Increases ADR [7]
------------------------------------------------------------------------------------
Indication(s) of Goserelin
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [4]
Estrogen-receptor positive breast cancer N.A. Approved [5]
Endometriosis GA10 Investigative [5]
Male breast carcinoma N.A. Investigative [5]
Goserelin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leutinizing-hormone-releasing hormone (GNRH1) TT0ID4A GON1_HUMAN Activator [8]
------------------------------------------------------------------------------------
Goserelin Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Decreases Expression [9]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Expression [10]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Expression [10]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Decreases Expression [10]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Decreases Secretion [11]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Prostate Cancer DC763GJ N. A. Phase 3 [12]
Prostate Cancer DC9C9SC N. A. Phase 3 [13]
Gastrointestinal Complications DCW1ETX N. A. Phase 3 [14]
Breast Cancer DCY45M7 N. A. Phase 2 [15]
Adenocarcinoma of the Prostate DC43XRL N. A. Phase 2 [16]
Recurrent Prostate Cancer DCLI0V7 N. A. Phase 2 [17]
Prostate Cancer DCVMLM2 N. A. Phase 2 [18]
Prostate Cancer DCHVXZQ N. A. Phase 1 [19]
Recurrent Prostate Cancer DC6Z3D7 N. A. Phase 1 [20]
Prostate Cancer DCTGJYL N. A. Phase 1 [21]
Adenocarcinoma of the Prostate DCD7XMI N. A. Phase 1 [22]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 ClinicalTrials.gov (NCT02941926) Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
2 Leuprolide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1175).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3879).
5 Goserelin FDA Label
6 Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
9 [Kuntai capsule combined with gonadotropin releasing hormone agonist in treatment of moderate-severe endometriosis: a clinical observation]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Nov;34(11):1288-91.
10 A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):94-103. doi: 10.1016/j.ejogrb.2006.07.042. Epub 2006 Sep 14.
11 Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. J Urol. 2006 Jul;176(1):354-60. doi: 10.1016/S0022-5347(06)00516-7.
12 ClinicalTrials.gov (NCT00388804) External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
13 ClinicalTrials.gov (NCT00002597) Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
14 ClinicalTrials.gov (NCT00541047) RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
15 ClinicalTrials.gov (NCT03056755) Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
16 ClinicalTrials.gov (NCT02058706) LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
17 ClinicalTrials.gov (NCT01750398) Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
18 ClinicalTrials.gov (NCT02059213) A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
19 ClinicalTrials.gov (NCT02366494) Micro RNAs to Predict Response to Androgen Deprivation Therapy
20 ClinicalTrials.gov (NCT00454571) Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
21 ClinicalTrials.gov (NCT00004635) Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
22 ClinicalTrials.gov (NCT02023463) Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer